<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 42-year-old woman with <z:e sem="disease" ids="C0085404" disease_type="Disease or Syndrome" abbrv="">Crow-Fukase syndrome</z:e> developed <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (M6: FAB classification) following treatment with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> (a total of 2,500 mg of melphalan and 9,800 mg of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>Chromosome analysis of the bone marrow showed 49,XX,der(1;7)(q10;p10), +8, +19, +21 in therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> with additional chromosomes 8, and 12 and two additional chromosomes 21 in <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Because of the risk of therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> should be used with caution in the treatment of <z:e sem="disease" ids="C0085404" disease_type="Disease or Syndrome" abbrv="">Crow-Fukase syndrome</z:e> </plain></SENT>
</text></document>